Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

August 22, 2018August 22, 2018

Aravive Biologics’ Therapy Earns FDA’s Fast Track Designation to Treat Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to AVB-S6-500 as a potential therapy for chemotherapy-resistant ovarian cancer, Aravive Biologics, the therapy’s developer, announced. Fast track designation is given ... Read more

July 27, 2018

Lynparza Maintenance for Ovarian Cancer Takes No Toll on Quality of Life, Study Shows

News

Ovarian cancer patients who responded to platinum-based chemotherapy after failing at least one prior treatment may take Lynparza (olaparib) as maintenance therapy without worrying about their quality of life, a new study ... Read more

July 16, 2018

Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), a PARP inhibitor, significantly prevents ovarian cancer from progressing or returning in women who responded to their first-line chemotherapy treatment, results from a Phase 3 trial show. The randomized, ... Read more

July 9, 2018

Kazia’s Cantrixil Shows Signs of Effectiveness in Advanced Ovarian Cancer Trial

News

Cantrixil, an investigative therapy which targets cancer cells that cause recurrence, shows promise as a treatment for ovarian cancer patients who failed at least two prior therapies, according to Australia-based Kazia ... Read more

June 25, 2018

Splash Begins Expansion Phase of SPL-108 Trial for Ovarian Cancer Patients

News

Splash Pharmaceuticals has successfully completed the safety stage of its Phase 1 trial testing a combination of SPL-108 and chemotherapy in platinum-resistant ovarian cancer patients, the company announced in a press release. Taking ... Read more

June 15, 2018June 15, 2018

Phase 3 Trial Evaluating Add-on Tecentriq for Advanced Ovarian Cancer Is Recruiting Participants

News

A new Phase 3 trial will evaluate the potential of Tecentriq (atezolizumab) as an add-on therapy to Avastin (bevacizumab) plus chemotherapy in advanced ovarian cancer patients. The trial, called ATALANTE (NCT02891824), ... Read more

May 30, 2018January 9, 2019

Phase 3 Trial to Assess TTFields plus Taxol in Platinum-resistant Ovarian Cancer Patients

News

A Phase 3 clinical trial will investigate the impact of adding Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, to Taxol (paclitaxel) for the treatment of ... Read more

May 23, 2018

Phase 2 Trial Seeking Patients for Zejula-Avastin Combo as Maintenance Therapy for Advanced Ovarian Cancer

News

Tesaro is recruiting for its Phase 2 trial testing its therapy Zejula (niraparib) plus Avastin (bevacizumab, Genentech) as a maintenance therapy for women with advanced ovarian cancer who achieved at least a ... Read more

April 2, 2018

Personalized Immunotherapy May Be Effective Ovarian Cancer Treatment, Study Finds

News

A new method that identifies and expands T-cells with high tumor-killing activity is a promising approach against ovarian cancer, a study shows. Findings could be used to develop a personalized, cell-based ... Read more

March 12, 2018March 12, 2018

Gene Mutations Increasing Ovarian Cancer Risk May Be Passed Down from Fathers, Study Suggests

News

Mutations in a newly identified gene that may increase women’s risk of ovarian cancer could be passed down through the X chromosome, a new study shows. The findings suggest that ... Read more